Literature DB >> 11159927

In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure.

A Wright1, Y Sato, T Okada, K Chang, T Endo, S Morrison.   

Abstract

We have now produced mouse-human chimeric IgG1 in wild-type Chinese hamster ovary (CHO) cell lines Pro-5 as well as in the glycosylation mutants Lec 2, Lec 8, and Lec 1. Analysis of the attached carbohydrates shows those present on IgG1-Lec 1 were mannose terminated. Carbohydrate present on IgG1-Lec8 was uniformly biantennary terminating in N-acetylglucosamine. The glycosylation profiles of IgG1-Lec 2 and IgG1-Pro-5 were heterogeneous. Only IgG1-Pro-5 was sialylated with sialic acid present on only a small percentage of the carbohydrate structures. When the in vivo fate of antibodies labeled with (125)I-lactotyramine was determined, it was found that the majority of all of the antibodies, irrespective of the structure of their attached carbohydrate, is catabolized in the skin and muscle. However, the attached carbohydrate structure does influence the amount that is catabolized in the liver and the liver serves as a major site for the catabolism of proteins bearing carbohydrate with the Lec2 (with terminal galactose) or Lec1(with terminal mannose) structure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11159927     DOI: 10.1093/glycob/10.12.1347

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  29 in total

Review 1.  Using glyco-engineering to produce therapeutic proteins.

Authors:  Martina Dicker; Richard Strasser
Journal:  Expert Opin Biol Ther       Date:  2015-07-14       Impact factor: 4.388

2.  Quantification of IgG monoclonal antibody clearance in tissues.

Authors:  Miro J Eigenmann; Ludivine Fronton; Hans Peter Grimm; Michael B Otteneder; Ben-Fillippo Krippendorff
Journal:  MAbs       Date:  2017-06-14       Impact factor: 5.857

3.  Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys.

Authors:  Maya K Leabman; Y Gloria Meng; Robert F Kelley; Laura E DeForge; Kyra J Cowan; Suhasini Iyer
Journal:  MAbs       Date:  2013 Nov-Dec       Impact factor: 5.857

4.  Straightforward Glycoengineering Approach to Site-Specific Antibody-Pyrrolobenzodiazepine Conjugates.

Authors:  Pamela Thompson; Ebele Ezeadi; Ian Hutchinson; Ryan Fleming; Binyam Bezabeh; Jia Lin; Shenlan Mao; Cui Chen; Luke Masterson; Haihong Zhong; Dorin Toader; Philip Howard; Herren Wu; Changshou Gao; Nazzareno Dimasi
Journal:  ACS Med Chem Lett       Date:  2016-09-20       Impact factor: 4.345

Review 5.  Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics.

Authors:  Daniela Bumbaca; C Andrew Boswell; Paul J Fielder; Leslie A Khawli
Journal:  AAPS J       Date:  2012-05-18       Impact factor: 4.009

Review 6.  ADME of antibody-maytansinoid conjugates.

Authors:  Hans K Erickson; John M Lambert
Journal:  AAPS J       Date:  2012-08-09       Impact factor: 4.009

Review 7.  Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

Authors:  Delphine Vivier; Sai Kiran Sharma; Brian M Zeglis
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-14       Impact factor: 1.921

8.  Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering.

Authors:  Hong Xu; Hongfen Guo; Irene Y Cheung; Nai-Kong V Cheung
Journal:  Cancer Immunol Res       Date:  2016-05-16       Impact factor: 11.151

9.  High-throughput glycosylation analysis of therapeutic immunoglobulin G by capillary gel electrophoresis using a DNA analyzer.

Authors:  Dietmar Reusch; Markus Haberger; Tobias Kailich; Anna-Katharina Heidenreich; Michael Kampe; Patrick Bulau; Manfred Wuhrer
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

10.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.

Authors:  Amit Garg; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-18       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.